Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein 3 pseudogene 42 (BNIP3P42)
- Target
- BNIP3P42
- Molecular classification
- Other (Pseudogene)
01
Overview
BCL2 interacting protein 3 pseudogene 42 (BNIP3P42) is a human pseudogene that does not produce a functional protein product, and therefore is not classified as an enzyme, receptor, transporter, or valid molecular target. Its sequence shares similarity with the coding gene BNIP3, which is involved in mitochondrial-mediated apoptosis, but the pseudogene does not participate in apoptosis or any established cellular processes. No functional, disease, or drug-related information is available for BNIP3P42, and its classification as a molecular target would be incorrect.
- Other names
- BCL2 interacting protein 3 pseudogene 42BCL2/adenovirus E1B 19kDa interacting protein 3 pseudogene 42BNIP3P42
02
Mechanism of action
None. There is no mechanism of action, as BNIP3P42 is not an actionable or functional molecular entity.
03
Biological functions
Due to being a pseudogene, BNIP3P42 lacks protein-coding function and thus does not participate directly in classical biological pathways.Pseudogenes are sometimes transcribed as RNA, but there is no evidence for BNIP3P42 producing meaningful biological activity; thus, biological function should be considered null.For related pseudogenes (e.g., BNIP3P1), there may be potential regulatory effects at the RNA level, such as acting as a competing endogenous RNA (ceRNA) influencing apoptosis or cell proliferation in disease, but no experimental proof for BNIP3P42 specifically is currently available.
04
Disease associations
None established for BNIP3P42 itself; no disease associations reported.
05
Safety considerations
None. Not applicable, as this is not a therapeutic or drug target.
06
Interacting drugs
None. No drugs interact with BNIP3P42, as it does not encode a protein.
07
Biomarkers
None. BNIP3P42 is not used as a biomarker for any clinical indications.
Beyond the preview
Go deeper on BCL2 interacting protein 3 pseudogene 42 (BNIP3P42).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 42 (BNIP3P42).